Skip to main content

Doctronic

Category: AI in Healthcare

An AI-powered healthcare platform for personalized medical assessments, symptom checking, and connecting patients with licensed doctors. Doctronic was founded in 2023. The company is led by Matt Pavelle. Based in New York, USA. Team size: 101-500. Total funding raised: $65M. Latest round: Series A, $20.0M, 2025-09, led by Lightspeed Venture Partners. Key investors include Union Square Ventures, Lightspeed Venture Partners, Abstract, Tusk Ventures, Mantis VC, Seven Stars, Wittington Ventures, ARTIS.

Founded
2023
Headquarters
New York, USA
Team size
101-500
Total funding
$65M

Value proposition

To provide fast, free, and personalized AI-driven medical guidance as a trustworthy alternative to online search engines, with a seamless and affordable option for video consultations with licensed doctors.

Products and solutions

AI-powered health assistant for symptom checking and medical information, Telehealth platform for video visits with licensed doctors

Unique value

Doctronic's core innovation is its use of AI agents for primary care triage, aiming to replace unreliable online self-diagnosis. It provides a trusted, interactive, and personalized healthcare experience that acts as a collaborative tool between the AI and human doctors.

Target customer

Individual consumers and patients seeking immediate, reliable medical information and affordable consultations.

Industries served

Healthcare, Digital Health, Telemedicine

Technology advantage

The company's main advantage is its scalable, AI-driven platform that offers initial medical consultations for free. This model efficiently funnels users who require further care to its integrated network of human doctors for a low-cost fee, creating an accessible and efficient healthcare solution.

How they differentiate

Doctronic differentiates itself by being an 'AI-first' platform that maintains a continuous care relationship, remembering a user's entire health history. Unlike telehealth services that primarily connect patients to human doctors, Doctronic provides an initial comprehensive assessment and ongoing guidance through its advanced AI, positioning itself as a superior alternative to searching for symptoms online ('Dr. Google').

Main competitors

Ro, Amwell, K Health

Key partnerships

Union Square Ventures (Investor), Tusk Ventures (Investor), HF0 (Startup Accelerator/Investor), Utah Department of Commerce / Office of AI Policy (AI Prescription Renewal Partnership), Abstract (Investor), Lightspeed Venture Partners (Investor)

Notable customers

Reportedly assisted in diagnosing a user's mystery illness, which was highlighted in a Fox Business interview.

Major milestones

Raised a $5M seed round led by Union Square Ventures., Secured a $20M Series A round., Surpassed 10 million AI-powered medical consultations., Became first AI legally authorized to renew prescriptions in the U.S. via Utah partnership (Dec 2025/Jan 2026)., Raised $40M Series B co-led by Abstract and Lightspeed Venture Partners (March 2026)., Surpassed 27 million AI-doctor visits., On track to earn $10M+ revenue in 2026.

Growth metrics

Publicly reported having completed over 27 million AI-doctor visits as of mid-2026, with more than 300,000 unique weekly visitors.

Market positioning

Doctronic is positioned as a primary care triage tool, aiming to be the first point of contact for users' health concerns. They market themselves as 'the world's most popular AI doctor,' focusing on providing accessible, personalized, and immediate health information.

Geographic focus

Based in New York, USA, Doctronic primarily focuses on the United States market.

Patents and IP

Information not publicly available.

About Matt Pavelle

Serial entrepreneur with a background in computer science from Carnegie Mellon University. Previously, he was the Founder and CEO of Pinata, a rewards and credit-building platform for renters, and the Founder and CEO of Mansion, a members-only luxury fashion platform.

Official website: